One million exomes identify FNIP1 as a metabolic brake.

Loss-of-function variants in FNIP1 are linked to reduced cardiometabolic disease risk in over 1 million exomes, highlighting FNIP1 as a metabolic brake.

• Why it matters: Understanding genetic factors that influence energy metabolism can reveal new targets for preventing cardiometabolic diseases, which remain a major health burden.
• What they did: Exome sequencing of more than 1 million individuals identified rare loss-of-function variants in FNIP1, a gene that suppresses mitochondrial energy expenditure.
• The result: Findings suggest that inhibiting FNIP1 may serve as a therapeutic strategy to lower cardiometabolic disease risk by modulating energy metabolism.